153 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information 5.
Exchange rates The Group uses the average of exchange rates prevailing during the period to translate the results and cash flows of overseas subsidiaries, joint ventures and associates into Sterling and period end rates to translate the net assets of those entities.
Turnover and segment information Operating segments are reported based on the financial information provided to the Chief Executive Officer and the responsibilities of the Corporate Executive Team CET.
GSK reports results under four segments: Pharmaceuticals: Pharmaceuticals R&D: Vaccines and Consumer Healthcare, and individual members of the CET are responsible for each segment.
The Groups management reporting process allocates intra-Group profit on a product sale to the market in which that sale is recorded, and the profit analyses below have been presented on that basis.
Corporate and other unallocated costs included the costs of corporate functions.
Revenue recognised in the year from performance obligations satisfied in previous periods totalled 426 million and included 122 million reported in turnover arising from changes to prior year estimates of RAR accruals and 299 million of royalty income.
2018 2017 2016 Turnover by segment m m m Pharmaceuticals 17,269 17,276 16,104 Vaccines 5,894 5,160 4,592 Consumer Healthcare 7,658 7,750 7,193 30,821 30,186 27,889 2018 2017 2016 Pharmaceuticals turnover by therapeutic area m m m Respiratory 6,928 6,991 6,510 HIV 4,722 4,350 3,556 Immuno-inflammation 472 377 340 Established Pharmaceuticals 5,147 5,558 5,698 17,269 17,276 16,104 2018 2017 2016 Vaccines turnover by category m m m Meningitis 881 890 662 Influenza 523 488 414 Shingles 784 22 Established Vaccines 3,706 3,760 3,516 5,894 5,160 4,592 During 2018, the US operations of the Pharmaceuticals and Vaccines businesses made sales to three wholesalers of approximately 2,709 million 2017 2,449 million: 2016 2,139 million, 2,962 million 2017 3,043 million: 2016 2,691 million and 2,656 million 2017 2,356 million: 2016 2,129 million respectively, after allocating final-customer discounts to the wholesalers.
Turnover and segment information continued 2018 2017 2016 Segment profit m m m Pharmaceuticals 8,420 8,667 7,976 Pharmaceuticals R&D 2,676 2,740 2,488 Pharmaceuticals, including R&D 5,744 5,927 5,488 Vaccines 1,943 1,644 1,429 Consumer Healthcare 1,517 1,373 1,116 Segment profit 9,204 8,944 8,033 Corporate and other unallocated costs 459 376 362 Other reconciling items between segment profit and operating profit 3,262 4,481 5,073 Operating profit 5,483 4,087 2,598 Finance income 81 65 72 Finance costs 798 734 736 Profit on disposal of interest in associates 3 94 Share of after tax profits of associates and joint ventures 31 13 5 Profit before taxation 4,800 3,525 1,939 Taxation 754 1,356 877 Profit after taxation for the year 4,046 2,169 1,062 Other reconciling items between segment profit and operating profit comprise items not specifically allocated to segment profit.
These include impairment and amortisation of intangible assets: major restructuring costs, which include impairments of tangible assets and computer software: transaction-related adjustments related to significant acquisitions: proceeds and costs of disposals of associates, products and businesses, significant legal charges and expenses on the settlement of litigation and government investigations, other operating income other than royalty income and other items, and the pre-tax impact of the enactment of the US Tax Cuts and Jobs Act.
2018 2017 2016 Depreciation and amortisation by segment m m m Pharmaceuticals 506 551 440 Pharmaceuticals R&D 123 96 211 Pharmaceuticals, including R&D 629 647 651 Vaccines 395 405 315 Consumer Healthcare 146 135 126 Segment depreciation and amortisation 1,170 1,187 1,092 Corporate and other unallocated depreciation and amortisation 106 144 94 Other reconciling items between segment depreciation and amortisation and total depreciation and amortisation 580 591 588 Total depreciation and amortisation 1,856 1,922 1,774 155 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information 6.
Turnover and segment information continued 2018 2017 2016 PP&E, intangible asset and goodwill impairment by segment m m m Pharmaceuticals 51 38 29 Pharmaceuticals R&D 15 10 88 Pharmaceuticals, including R&D 66 48 117 Vaccines 5 13 34 Consumer Healthcare 4 10 46 Segment impairment 75 71 197 Corporate and other unallocated impairment 14 3 24 Other reconciling items between segment impairment and total impairment 261 995 68 Total impairment 350 1,069 289 PP&E and intangible asset impairment reversals by segment Pharmaceuticals 4 13 15 Pharmaceuticals R&D 1 2 10 Pharmaceuticals, including R&D 5 15 25 Vaccines 19 Consumer Healthcare 1 8 Segment impairment reversals 5 16 52 Corporate and other unallocated impairment reversals 26 Other reconciling items between segment impairment reversals and total impairment reversals 8 36 9 Total impairment reversals 13 52 87 2018 2017 Net assets by segment m m Pharmaceuticals 869 2,017 Pharmaceuticals R&D 502 522 Pharmaceuticals, including R&D 1,371 2,539 Vaccines 9,966 9,707 Consumer Healthcare 10,559 2,003 Segment net operating assets 21,896 14,249 Corporate and other unallocated net operating assets 1,141 868 Net operating assets 23,037 15,117 Net debt 21,621 13,178 Investments in associates and joint ventures 236 183 Derivative financial instruments 129 2 Current and deferred taxation 1,723 1,252 Assets held for sale excluding cash and cash equivalents 168 113 Net assets 3,672 3,489 The Pharmaceuticals segment includes the Shionogi-ViiV Healthcare contingent consideration liability of 5,937 million 2017 5,542 million and the Pfizer put option of 1,240 million 2017 1,304 million.
The put option liability 2017 8,606 million related to the Consumer Healthcare segment was extinguished during 2018.
